[Prioritization of chemotherapy drugs in the Catalan hospital system: a qualitative case study]
1Pla Director d'Oncologia, Departament de Salut, Hospitalet de Llobregat, Barcelona, España. jlprades@iconcologia.net
Objectives:
To analyze the prioritization process for chemotherapy drugs in the Drug-Therapeutic Committees (DTCs) in Catalan hospitals and assess their impact on patients' access to these drugs.
Methods:
A case qualitative study of the DTCs of tertiary hospitals in Catalonia was performed, based on semi-structured interviews and a review of the scientific literature. Key professionals were interviewed with technical and institutional involvement in the DTCs assessment process, including pharmacists, oncologists, clinical pharmacologists and other physicians with different medical specialties. The conceptual framework "accountability for reasonableness", by Daniels and Sabin, which analyzes prioritization processes from a "fair and legitimate decision-making" perspective, was used.
Results:
The current regulatory framework for the introduction of drugs is characterized by a fragmented hospital system and lacks coordination strategies. These weaknesses fail to allow the prioritization and optimization of resources in the Catalan health service.
Conclusion:
We propose the implementation of a decision-making coordination strategy for all public sector hospitals. This strategy would allow an increasingly innovative environment to be exploited, in which inequalities in access to drugs at the hospital level should be avoided.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer Survival Analysis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

